Pathology, one of the last major diagnostic disciplines to fully digitize, is now firmly on that path. As hospitals, diagnostic labs, and life sciences companies look for faster turnaround times and more consistent diagnoses, digital pathology has moved from a niche research tool to a mainstream part of clinical and pharmaceutical workflows.

According to Grand View Research, the global digital pathology market was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 3.0 billion by 2033, expanding at a CAGR of 8.6% over the forecast period. North America led the market in 2025 with a 39.92% revenue share, while As      a Pacific is expected to post the fastest growth through 2033.

Here's a closer look at what's fueling this growth, the trends shaping the industry, the hurdles still standing in the way, and how different regions and segments are performing.

What's Driving the Market

• Rising cancer burden and demand for precision diagnostics. The single biggest driver behind digital pathology adoption is the growing global cancer caseload. Pathologists need tools that can process tissue data quickly and help tailor therapies to individual patients, and digital pathology delivers on both fronts — accelerating diagnosis, improving accuracy, and supporting therapeutic decision-making. Academic research into deep learning models for image segmentation and classification in breast cancer diagnosis is one example of how far the underlying technology has advanced.
• Demand for integrated, patient-centric healthcare systems. Health systems are increasingly moving toward integrated records that can be accessed across multiple facilities. This is pushing vendors toward more connected digital pathology offerings. A good example is the February 2025 expansion of the partnership between Charles River Laboratories and Deciphex, which is focused on building AI-powered image management tools for toxicologic pathology.
• Growth in veterinary pathology. AI is making inroads into veterinary medicine just as it has in human diagnostics, particularly in preclinical drug research. Fewer regulatory restrictions around virtual slide-based veterinary diagnoses are accelerating adoption. Proscia's 2024 partnership with veterinary lab SpecialtyVETPATH to move toward a fully digital workflow illustrates this shift.
• Wider healthcare IT adoption. Organizations are turning to digital pathology as part of broader healthcare IT investment aimed at cutting costs, easing resource bottlenecks, and enabling smoother collaboration and content sharing across teams and institutions.
• AI-driven automation. AI is increasingly handling tasks that used to require manual review — like identifying regions of interest in tissue samples — cutting down on human error and freeing up pathologist time.

Key Trends to Watch

• AI in digital pathology is becoming its own growth engine. A dedicated ecosystem of AI-native digital pathology companies — including Proscia, Aignostics, Aiforia, and Mindpeak — is emerging alongside traditional imaging vendors. Falling hardware costs, rising healthcare data volumes, and a wave of venture capital investment are all reinforcing this shift.
• Drug discovery and precision medicine are opening new doors. Pharma and biotech companies are leaning on digital pathology for translational research, biomarker analysis, and companion diagnostics. Research commissioned by Proscia found that nearly 75% of surveyed life sciences organizations had already invested in digital pathology to strengthen their R&D capabilities. As spatial biology and genomics increasingly intersect with pathology imaging, this opportunity is only expanding.
• Software leads, but devices are catching up fast. Software held the largest product share in 2025 at 42.88%, driven by platforms like Roche's uPath and Xybion's Pristima XD. But the device segment — scanners and slide management systems — is expected to grow even faster, powered by rising academic research activity and higher-resolution imaging needs.
• Oncology remains the anchor use case, but cardiovascular is rising. Oncology accounted for 52.02% of revenue in 2025, unsurprising given that cancer remains one of the leading causes of death worldwide. Cardiovascular applications, however, are forecast to grow the fastest as AI-enabled tissue characterization tools mature.
• A moderately consolidated, innovation-heavy market. The competitive landscape is described as slightly fragmented, with many vendors entering the space, high levels of partnership activity, and strong regulatory influence from bodies like the FDA and HIPAA. M&A activity is moderate — Fujifilm's 2023 acquisition of Inspirata's digital pathology business, including its Dynamyx system, is a notable example — while regional expansion is progressing steadily rather than explosively.

Want deeper data on vendors, regional forecasts, or segment-level opportunities? Explore the full market report and download a free sample at Grand View Research to inform your next strategic decision.

Challenges Facing the Market

Despite the strong growth outlook, the market isn't without friction points:

• Workflow disruption during transition. Labs moving from traditional microscopy to digital workflows often face resistance from staff accustomed to established processes, along with the operational challenge of integrating new systems without slowing down diagnostic throughput.
• Infrastructure and data management costs. Digitized slides generate enormous volumes of data, and building the scanning hardware and IT infrastructure to manage it requires significant upfront investment.
• Regulatory complexity. Compliance with data integrity, security, and privacy regulations — including FDA requirements, HIPAA, and Clinical Laboratory Improvement Amendments — adds cost and complexity to deployment, especially for companies operating across multiple regions.
• Illegitimate products in adjacent markets. In the veterinary pathology space specifically, counterfeit and unregistered veterinary medicines and compounded products pose safety risks and can undermine trust in the broader ecosystem of digital veterinary diagnostics.

The experience of IMP Diagnostics, a private pathology lab in Portugal, is a useful illustration of how labs are navigating these challenges — introducing barcode-based sample tracking, phasing in digitization gradually, and investing in staff training rather than attempting a disruptive, all-at-once rollout.

Regional Insights

• North America led the market in 2025 with a 39.92% revenue share, supported by strong government backing for advanced pathology infrastructure, continuous R&D investment, and a concentration of major industry players. The U.S. leads within the region, helped by a mature healthcare infrastructure, high per-capita healthcare spending, and a growing number of FDA-cleared AI tools for cancer and skin lesion detection.
• Europe is expected to grow at a solid pace, driven by high chronic disease prevalence and a dense network of diagnostic imaging centers. Government-backed research initiatives are playing a meaningful role — the European Institute of Biomedical Imaging Research alone has invested more than USD 66.84 million in biomedical imaging research over the past decade. The UK and Germany stand out as active national markets, each supported by clear digital pathology guidelines and rising cancer case volumes.
• Asia Pacific is forecast to be the fastest-growing region through 2033, propelled by rapid digitalization, rising medical investment, and expanding digital imaging adoption across developing economies. China and Japan are key growth engines — China through partnerships like Aignostics' 2023 collaboration with Virchow Laboratories, and Japan through steady technological advancement and stronger early cancer detection initiatives.
• Latin America is seeing meaningful growth as healthcare awareness improves, cancer prevalence rises, and local labs form partnerships with international digital pathology vendors.
• Middle East & Africa remains an emerging market shaped largely by unmet pathology service needs, with telepathology — often supported by European collaborators — playing an outsized role in extending diagnostic access.

The Road Ahead

Digital pathology's trajectory over the next several years looks less like a niche technology upgrade and more like a fundamental shift in how tissue-based diagnosis happens — from slide to screen, and increasingly, from manual review to AI-assisted analysis. The convergence of imaging, AI, genomics, and precision medicine is creating opportunities well beyond traditional diagnostic labs, reaching into drug discovery, veterinary medicine, and remote care delivery.

For healthcare providers, diagnostic labs, and life sciences companies, the strategic question is no longer whether to adopt digital pathology, but how fast and in what sequence — balancing infrastructure investment, staff readiness, and regulatory compliance against the competitive cost of standing still.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore our dedicated business services:

• U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.